Dimitriou et al.retrospectively concluded that immunomodulatory drugs such as anti-TNFαand anti-IL-6 agents had no effect on the efficacy of ICIs in melanomapatients.49 There have been some casesof hepatitis reported with infliximab, and it is therefore often avoidedin cases of hepatitis, though evolving evidence is suggestive of benefitin certain cases, particularly in the treatment of refractory hepatitisand sclerosing cholangitis. This evidence concerns the gene IL6 and Hepatitis.